Exploration of Synergistic Effects: RAF Dimer Inhibitor Lifirafenib (BGB- 283) & MEK Inhibitor Mirdametinib (PD-0325901)
Time: 9:20 am
day: Day Two
- How can inhibiting RAF dependent MEK reactivation suppress the proliferation of KRAS mutated cancer cells?
- Discuss methodologies of inhibiting tumor growths in KRAS mutant xenograft models
- Deconstruct the pharmacodynamic analysis of synergistic phospho-ERK blockade to confirm the antitumor activity in the KRAS mutant models
- Explore the decision to support a vertical inhibition strategy